NO20084488L - Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith - Google Patents
Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewithInfo
- Publication number
- NO20084488L NO20084488L NO20084488A NO20084488A NO20084488L NO 20084488 L NO20084488 L NO 20084488L NO 20084488 A NO20084488 A NO 20084488A NO 20084488 A NO20084488 A NO 20084488A NO 20084488 L NO20084488 L NO 20084488L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- functional protein
- methods
- dna
- production
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78733306P | 2006-03-30 | 2006-03-30 | |
US81308506P | 2006-06-12 | 2006-06-12 | |
PCT/US2007/008268 WO2007117438A2 (fr) | 2006-03-30 | 2007-03-29 | Méthodes de production d'une protéine fonctionnelle à partir d'un adn présentant une mutation non-sens et traitement des troubles associés |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20084488L true NO20084488L (no) | 2008-12-19 |
Family
ID=38480572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20084488A NO20084488L (no) | 2006-03-30 | 2008-10-24 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith |
Country Status (15)
Country | Link |
---|---|
US (2) | US9289398B2 (fr) |
EP (2) | EP2007365A2 (fr) |
JP (2) | JP5367563B2 (fr) |
CN (1) | CN101505739A (fr) |
AU (1) | AU2007235524B2 (fr) |
BR (1) | BRPI0710213A2 (fr) |
CA (1) | CA2647903C (fr) |
IL (2) | IL194454A (fr) |
IN (1) | IN2014CN04406A (fr) |
MX (1) | MX2008012515A (fr) |
NO (1) | NO20084488L (fr) |
NZ (2) | NZ596965A (fr) |
RU (1) | RU2462246C2 (fr) |
SG (1) | SG170819A1 (fr) |
WO (1) | WO2007117438A2 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE031794T2 (en) | 2003-04-11 | 2017-08-28 | Ptc Therapeutics Inc | 1,2,4-oxadiol-benzoic acid compounds and their use for nonsense suppression and disease treatment |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
WO2010123369A1 (fr) | 2009-04-24 | 2010-10-28 | Prosensa Technologies B.V. | Oligonucléotide comprenant une inosine pour traiter une dystrophie musculaire de duchenne (dmd) |
EP2251437B1 (fr) * | 2009-05-13 | 2013-12-04 | Hannelore Breitenbach-Koller | Procédé d'identification de composés qui contrôlent l'activité translationnelle des protéines ribosomales dans l'expression mRNA différentielle |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
CA2862628C (fr) | 2012-01-27 | 2021-08-24 | Prosensa Technologies B.V. | Oligonucleotides a modulation d'arn dotes de caracteristiques ameliorees pour le traitement de la dystrophie musculaire de duchenne et de becker |
US9604961B2 (en) | 2012-12-06 | 2017-03-28 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
CN103074346A (zh) * | 2013-01-22 | 2013-05-01 | 山西大学 | 一种用于促通读药物筛选的有限细胞株的建立方法 |
WO2015051214A1 (fr) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucléotides codant pour un récepteur de lipoprotéines de faible densité |
KR102497273B1 (ko) * | 2014-03-06 | 2023-02-07 | 피티씨 테라퓨틱스, 인크. | 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염 |
ES2957761T3 (es) * | 2014-04-15 | 2024-01-25 | Vertex Pharma | Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística |
JP2016155900A (ja) * | 2015-02-23 | 2016-09-01 | 株式会社フジミインコーポレーテッド | 研磨用組成物、研磨方法及び硬脆材料基板の製造方法 |
MX2018005361A (es) | 2015-10-30 | 2018-06-07 | Ptc Therapeutics Inc | Metodos para tratar epilepsia. |
WO2017112956A1 (fr) | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Procédés pour induire une réponse immunitaire |
EP3512516A1 (fr) * | 2016-09-13 | 2019-07-24 | Marco Cipolli | Procédé de traitement du syndrome de shwachman-diamond |
US11654135B2 (en) | 2017-06-22 | 2023-05-23 | Moonshot Pharma Llc | Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors |
CN107916252B (zh) * | 2017-11-17 | 2021-01-22 | 首都儿科研究所 | 一株用于验证脊肌萎缩症的永生淋巴细胞株 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL291628A (fr) * | 1962-04-17 | |||
US3325446A (en) * | 1964-04-17 | 1967-06-13 | Allied Chem | Stabilized halogen-containing olefin polymer compositions and stabilizers therefor |
US4022901A (en) * | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
JPS51143669A (en) | 1975-06-06 | 1976-12-10 | Takeda Chem Ind Ltd | A process for preparing 1,2,4- oxadiazole derivatives |
US4016170A (en) * | 1975-07-28 | 1977-04-05 | Sandoz, Inc. | Oxadiazolyl benzamides |
US4166732A (en) * | 1977-05-12 | 1979-09-04 | Monsanto Company | Oxadiazol-5-yl-benzoates |
US4135910A (en) * | 1977-05-12 | 1979-01-23 | Monsanto Company | Oxadiazol-3-yl-benzoates as plant growth regulants |
US4268299A (en) * | 1978-08-17 | 1981-05-19 | Monsanto Company | Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates |
US4210762A (en) * | 1978-08-17 | 1980-07-01 | Monsanto Company | 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates |
EP0036711B1 (fr) * | 1980-03-22 | 1985-12-04 | Fbc Limited | Composés hétérocycliques pesticides, procédés pour leur préparation, compositions les contenant, et leur utilisation |
DE3148449C1 (de) | 1981-12-08 | 1983-06-01 | Heidelberger Druckmaschinen Ag, 6900 Heidelberg | Verfahren zur Verringerung von Registerfehlern und Druckmaschine zur Durchfuehrung des Verfahrens |
GB8802142D0 (en) | 1988-02-01 | 1988-03-02 | Air Prod & Chem | Method of freezing liquid & pasty products & freezer for carrying out said method |
US5037052A (en) | 1989-04-21 | 1991-08-06 | Crisp Joe E | Clamp assembly system |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US5036761A (en) | 1989-11-20 | 1991-08-06 | Wingo Patrick Y | Forced flow press dampening apparatus |
US4984286A (en) | 1989-12-12 | 1991-01-08 | Analogic Corporation | Spatial filter system |
US5036762A (en) | 1990-06-12 | 1991-08-06 | Sarda Jean Lucien | Apparatus for supplying offset printing presses with a cooled damping solution |
AU660629B2 (en) | 1990-10-01 | 1995-07-06 | University Of Connecticut, The | Targeting viruses and cells for selective internalization by cells |
JPH06510524A (ja) | 1991-05-14 | 1994-11-24 | ユニバーシティ オブ コネチカット | 免疫原性タンパク質をコードする遺伝子の標的への配達 |
DE69231385T2 (de) | 1991-06-05 | 2001-04-12 | Univ Connecticut Storrs | Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren |
WO1993014188A1 (fr) | 1992-01-17 | 1993-07-22 | The Regents Of The University Of Michigan | Virus cible |
AU3940293A (en) | 1992-04-03 | 1993-11-08 | Alexander T. YOUNG | Gene therapy using targeted viral vectors |
WO1994008598A1 (fr) | 1992-10-09 | 1994-04-28 | Advanced Tissue Sciences, Inc. | Cellules hepatiques de reserve |
EP0905253A3 (fr) | 1992-12-03 | 2000-11-02 | Genzyme Corporation | Vecteur adenovira délété de tous les ORF de E4 excepté ORF6 |
DE4320801A1 (de) | 1993-06-23 | 1995-01-05 | Fahlberg List Pharma Gmbh | 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel |
US5484944A (en) * | 1993-10-27 | 1996-01-16 | Neurogen Corporation | Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands |
US5942496A (en) | 1994-02-18 | 1999-08-24 | The Regent Of The University Of Michigan | Methods and compositions for multiple gene transfer into bone cells |
US5962427A (en) | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
RU2164419C2 (ru) * | 1994-03-18 | 2001-03-27 | Мириад Дженетикс, Инк. | Ген mts, мутации данного гена и способы диагностики злокачественных опухолей с использованием последовательности гена mts |
TW343965B (en) | 1994-03-30 | 1998-11-01 | Hoffmann La Roche | Novel mono- and bicyclic DNA gyrase inhibitors |
EP0853626A1 (fr) | 1995-09-07 | 1998-07-22 | Novartis AG | Composes phosphiniques substitues et leur utilisation pharmaceutique |
DE19620041A1 (de) | 1996-05-17 | 1998-01-29 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
US6034106A (en) * | 1996-06-07 | 2000-03-07 | Merck & Co., Inc. | Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity |
WO1997046556A1 (fr) | 1996-06-07 | 1997-12-11 | Merck & Co., Inc. | BENZENESULFONAMIDES D'OXADIAZOLE EN TANT QU'AGONISTES β3 SELECTIFS POUR LE TRAITEMENT DU DIABETE ET DE L'OBESITE |
DE19626318A1 (de) | 1996-07-01 | 1998-01-08 | Basf Ag | Farbstoffmischungen, enthaltend Polyazofarbstoffe |
ZA98371B (en) | 1997-01-31 | 1999-07-16 | Du Pont | Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides. |
EP0975595B9 (fr) * | 1997-04-07 | 2009-09-16 | Georgetown University | Analogues de cocaine |
US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
TR200002482T2 (tr) * | 1998-02-26 | 2002-10-21 | Aventis Pharmaceuticals Inc. | 6,9-Diikameli 2-(Trans-(4-Aminosiklohekzil) Amino)Pürinler |
WO1999054317A1 (fr) | 1998-04-23 | 1999-10-28 | Cortech Inc. | Inhibiteurs de cysteine proteases |
AU763460B2 (en) | 1998-10-09 | 2003-07-24 | Janssen Pharmaceutica N.V. | 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
AU1455500A (en) | 1998-10-29 | 2000-05-22 | Trega Biosciences, Inc. | Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof |
PL350132A1 (en) | 1998-12-23 | 2002-11-04 | Smithkline Beecham Corp | Protease inhibitors |
WO2000052467A1 (fr) * | 1999-03-02 | 2000-09-08 | The University Of Dundee | Methodes de determination des fonctions ndpk modifiees |
AU3196200A (en) | 1999-03-26 | 2000-10-16 | Shionogi & Co., Ltd. | Beta-amino acid derivatives |
WO2000058304A1 (fr) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Derives sulfonamides heterocycliques |
WO2000058280A1 (fr) | 1999-03-26 | 2000-10-05 | Shionogi & Co., Ltd. | Derives de sulfonamide carbocyclique |
EP1183229B1 (fr) | 1999-05-17 | 2005-10-26 | Novo Nordisk A/S | Antagonistes/agonistes inverses de glucagon |
UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
JP2001247569A (ja) | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US6458538B1 (en) | 1999-12-14 | 2002-10-01 | Ptc Therapeutics, Inc. | Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay |
WO2001066534A2 (fr) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Antagonistes du recepteur d'histamine-3 diamino cycliques et bicycliques |
CA2401984A1 (fr) * | 2000-03-22 | 2001-09-27 | Merck Frosst Canada Inc. | Acides aryldifluoromethyl phosphoniques substitues soufre en tant qu'inhibiteurs de as ptp-1b |
GB0011089D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (11) |
CN1230431C (zh) | 2000-05-22 | 2005-12-07 | 阿温蒂斯药物公司 | 用作类胰蛋白酶抑制剂的芳基甲胺衍生物 |
US7366402B2 (en) | 2000-06-02 | 2008-04-29 | Lg Electronics Inc. | Method and apparatus of recording a high definition digital television broadcast signal |
JP2002105073A (ja) | 2000-09-27 | 2002-04-10 | Shionogi & Co Ltd | 新規マトリックスメタロプロテアーゼ阻害剤 |
AUPR362001A0 (en) | 2001-03-08 | 2001-04-05 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
MXPA03009548A (es) | 2001-04-19 | 2004-05-24 | Bayer Ag | Arilsulfonamidas como agentes antivirales. |
CA2449544A1 (fr) | 2001-06-08 | 2002-12-19 | Cytovia, Inc. | 3-aryl-5-aryl-[1,2,4]-oxadiazoles et leurs analogues, activateurs des caspases et inducteurs de l'apoptose, et leurs utilisations |
GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
MY151199A (en) * | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
US7291461B2 (en) * | 2002-06-21 | 2007-11-06 | Ptc Therapeutics, Inc. | Methods for identifying small molecules that modulate premature translation termination and nonsense mRNA decay |
US7291603B2 (en) | 2002-07-24 | 2007-11-06 | Ptc Therapeutics, Inc. | Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations |
AU2003256755A1 (en) | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
WO2004010106A2 (fr) | 2002-07-24 | 2004-01-29 | Ptc Therapeutics, Inc. | Methodes destinees a identifier des petites molecules modulant la terminaison de traduction prematuree et la degradation de l'arnm induite par mutation non-sens |
CA2493457A1 (fr) | 2002-07-24 | 2004-01-29 | Ptc Therapeutics, Inc. | Composes d'acide acetylamino benzoique et leur utilisation pour la suppression de non-sens et le traitement de maladie |
CA2495179A1 (fr) | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Nouveaux composes |
CN1691944A (zh) | 2002-08-09 | 2005-11-02 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体-5调节剂的噁二唑 |
GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
US7555125B2 (en) | 2003-08-14 | 2009-06-30 | Broadcom Corporation | Systems and methods for generation of time-dependent control signals for video signals |
HUE031794T2 (en) * | 2003-04-11 | 2017-08-28 | Ptc Therapeutics Inc | 1,2,4-oxadiol-benzoic acid compounds and their use for nonsense suppression and disease treatment |
US20050075375A1 (en) | 2003-05-14 | 2005-04-07 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis C virus |
JP3852934B2 (ja) | 2003-05-20 | 2006-12-06 | 株式会社バンダイナムコゲームス | 画像処理システム、プログラム及び情報記憶媒体 |
US20050037052A1 (en) | 2003-08-13 | 2005-02-17 | Medtronic Vascular, Inc. | Stent coating with gradient porosity |
KR100565056B1 (ko) | 2003-08-14 | 2006-03-30 | 삼성전자주식회사 | Av 데이터를 enav 모드로 재생하는 방법, 그 장치및 그 정보저장매체 |
WO2005060961A2 (fr) | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Nouveau traitement du reflux gastrooesophagien pathologique |
WO2005077373A2 (fr) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Nouveau traitement du reflux gastro-oesophagien pathologique ii |
US20080207538A1 (en) * | 2004-03-11 | 2008-08-28 | Lawrence David S | Enhanced Production of Functional Proteins From Defective Genes |
DE102004013599A1 (de) * | 2004-03-19 | 2005-10-06 | Robert Bosch Gmbh | Ansteuerschaltung zum Ansteuern einer leistungselektronischen Schaltung sowie Verfahren hierzu |
EP2363129A1 (fr) * | 2004-10-13 | 2011-09-07 | PTC Therapeutics, Inc. | Composes de suppression de non-sens et procedes de leur utilisation |
ES2390804T3 (es) | 2005-04-08 | 2012-11-16 | Ptc Therapeutics, Inc. | Composiciones de un 1,2,4-oxadiazol oralmente activo para terapia de supresión de la mutación sin sentido |
CA2662749C (fr) * | 2006-09-08 | 2015-01-20 | Ptc Therapeutics, Inc. | Procedes de preparation d'acides 1,2,4-oxadiazole benzoiques |
AU2007300542B2 (en) * | 2006-09-25 | 2012-05-17 | Ptc Therapeutics, Inc. | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
US8101641B2 (en) * | 2006-09-25 | 2012-01-24 | Ptc Therapeutics, Inc. | Hydroxylated 1,2,4-oxadiazole benzoic acid compounds and compositions thereof |
JP2010506840A (ja) * | 2006-10-12 | 2010-03-04 | ピーティーシー セラピューティクス,インコーポレーテッド | ナンセンス突然変異抑制治療用の経口的に活性な1,2,4−オキサジアゾールの投与方法 |
WO2009151546A2 (fr) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Procédés de traitement d'une atrophie musculaire spinale |
-
2007
- 2007-03-29 EP EP07754745A patent/EP2007365A2/fr not_active Withdrawn
- 2007-03-29 NZ NZ596965A patent/NZ596965A/xx not_active IP Right Cessation
- 2007-03-29 EP EP11152243A patent/EP2387995A1/fr not_active Withdrawn
- 2007-03-29 CA CA2647903A patent/CA2647903C/fr not_active Expired - Fee Related
- 2007-03-29 AU AU2007235524A patent/AU2007235524B2/en not_active Ceased
- 2007-03-29 RU RU2008142957/15A patent/RU2462246C2/ru not_active IP Right Cessation
- 2007-03-29 SG SG201102327-2A patent/SG170819A1/en unknown
- 2007-03-29 NZ NZ571899A patent/NZ571899A/en not_active IP Right Cessation
- 2007-03-29 IN IN4406CHN2014 patent/IN2014CN04406A/en unknown
- 2007-03-29 CN CNA2007800201278A patent/CN101505739A/zh active Pending
- 2007-03-29 JP JP2009503082A patent/JP5367563B2/ja not_active Expired - Fee Related
- 2007-03-29 MX MX2008012515A patent/MX2008012515A/es active IP Right Grant
- 2007-03-29 WO PCT/US2007/008268 patent/WO2007117438A2/fr active Application Filing
- 2007-03-29 BR BRPI0710213-5A patent/BRPI0710213A2/pt not_active IP Right Cessation
- 2007-03-29 US US12/294,952 patent/US9289398B2/en not_active Expired - Fee Related
-
2008
- 2008-09-28 IL IL194454A patent/IL194454A/en not_active IP Right Cessation
- 2008-10-24 NO NO20084488A patent/NO20084488L/no not_active Application Discontinuation
-
2012
- 2012-10-18 IL IL222557A patent/IL222557A/en active IP Right Grant
-
2013
- 2013-06-25 JP JP2013133071A patent/JP5798154B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-16 US US15/044,225 patent/US20160199357A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP5367563B2 (ja) | 2013-12-11 |
IL194454A (en) | 2013-01-31 |
JP2009532368A (ja) | 2009-09-10 |
IL222557A (en) | 2016-09-29 |
WO2007117438A3 (fr) | 2008-10-23 |
CN101505739A (zh) | 2009-08-12 |
SG170819A1 (en) | 2011-05-30 |
WO2007117438A2 (fr) | 2007-10-18 |
CA2647903C (fr) | 2016-12-13 |
IL222557A0 (en) | 2012-12-31 |
AU2007235524B2 (en) | 2013-09-12 |
RU2462246C2 (ru) | 2012-09-27 |
NZ571899A (en) | 2012-07-27 |
MX2008012515A (es) | 2008-11-19 |
BRPI0710213A2 (pt) | 2011-04-12 |
RU2008142957A (ru) | 2010-05-10 |
US9289398B2 (en) | 2016-03-22 |
EP2387995A1 (fr) | 2011-11-23 |
IN2014CN04406A (fr) | 2015-09-04 |
NZ596965A (en) | 2013-06-28 |
JP5798154B2 (ja) | 2015-10-21 |
IL194454A0 (en) | 2009-08-03 |
US20160199357A1 (en) | 2016-07-14 |
JP2013234189A (ja) | 2013-11-21 |
EP2007365A2 (fr) | 2008-12-31 |
CA2647903A1 (fr) | 2007-10-18 |
AU2007235524A1 (en) | 2007-10-18 |
US20110046136A1 (en) | 2011-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20084488L (no) | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | |
WO2007087451A3 (fr) | Compositions et procedes d’accroissement des interferences arn discriminatoires | |
WO2009059318A3 (fr) | Gènes et polymorphismes associés à l'amd | |
CY1120384T1 (el) | Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων | |
DK2049664T3 (da) | Enkeltstrengede oligonukleotider, som er komplementære til repetitive elementer, til behandling af med DNA-repetitiv-ustabilitet associerede lidelser | |
EA201591281A1 (ru) | Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы | |
MA32771B1 (fr) | Mutants fgf21 et leurs utilisations | |
EP2639319A3 (fr) | Polymorphismes génétiques associés au psoriasis, procédés de détection et utilisations associées | |
WO2008104978A3 (fr) | Nouvelles structures d'arnsi | |
WO2009090639A3 (fr) | Composés d'arnsi et leurs utilisations | |
WO2010056982A3 (fr) | Compositions et procédés pour identifier des troubles du spectre de l'autisme | |
DK1730315T3 (da) | Polymorphismer i NOD2/Card15 gen | |
SG179410A1 (en) | Therapeutic uses of inhibitors of rtp801 | |
WO2010083207A3 (fr) | Inhibiteurs de la protéine kinase c et leurs utilisations | |
WO2008087641A3 (fr) | Agents nucléotidiques de silençage de h19 destinés au traitement de l'arthrite rhumatoïde | |
WO2008086079A3 (fr) | Compositions thérapeutiques comprenant un agent arni et un facteur neurotrophique et leurs procédés d'utilisation | |
WO2004096842A3 (fr) | Sequences de nucleotides et d'acides amines du virus du sras, et utilisations associees | |
MX2009008425A (es) | Derivados de 1-bencensulfonil-1h-indol como inhibidores de la actividad de ccr9. | |
WO2008143774A3 (fr) | Procédés et compositions permettant de déterminer l'hétérozygocité snp dans le cadre d'un diagnostic et d'une thérapie allèle-spécifiques | |
WO2007149521A3 (fr) | Motifs nucléotidiques produisant des éléments de localisation et procédés d'utilisation | |
EP4324936A3 (fr) | Procédé de détection de la fibrose kystique | |
TW200724679A (en) | Treatment of disease using an improved regulated expression system | |
WO2009147658A3 (fr) | Compositions et procédés pour le diagnostic, le pronostic et le traitement d'un mésothéliome | |
UA93658C2 (en) | Cell surface glycoprotein | |
WO2008125222A3 (fr) | Nouvelles molécules de modulation destinées à un système d'expression régulée amélioré |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |